Covid-19: Heed lessons ‘or risk a monkeypox disaster’
An outbreak of monkeypox has created a barometer on how much the world has learned from Covid-19 and how to better fund biotech companies.
Csl
100-day target for new Covid-19 vaccines
Researchers are under mounting pressure to deliver with the development of new vaccines now slashed to 100 days after first Covid-19 shot took a year.
Climate diplomacy underlines defence gap
Taking action on climate change is seen by the government as a strategy to meet the emerging China threat in the Pacific. But its first duty is to secure the nation’s defence.
ASX falls; BHP, Fortescue, Rio hit 8-month lows
Fresh recession jitters sends ASX lower as materials and energy plunge. Megaport and Zip surge, St Barbara falls sharply, CSL hits six-month high and Bitcoin below $US20,000.
No shame in changing our mind about the elephant in the room
No one seriously believes solar and wind alone will propel us to a 43 per cent reduction in CO2 emissions by 2030 — but the facts on nuclear power have altered significantly in the past two decades.
ASX adds 0.3pc; CSL, Goodman, Blackmores lifts
ASX rebounds led by real estate and health. Lake Resources crashes as it calms investors, NBN taps bond market, Growthpoint jumps on forecast and PayGroup’s stunning surge.
Small nuclear reactors would get us to carbon neutral
If the anti-nukers hadn’t interfered, Australia would have a clean, green energy source by now – and we’d be a richer nation for it.
ASX flat; CSL, NAB, ANZ lead declines
ASX trims gains as a China Covid surge spooks traders. Geoff Wilson against AGL demerger, Codan up on profit beat, Incitec slips on demerger plans and outgoing Star chair gives evidence.
ASX jumps 1.9pc; tech, health care drive gains
ASX posts its third best session for 2022 as tech stocks lead charge. Block jumps 15 per cent as IGO lags, BGH extends Virtus offer, Star director to quit and bitcoin leaps.
ASX rises in volatile trade; CSL leads gains
ASX ends three-day losing streak ahead of US inflation numbers. CSL leads health care rally, Link plunges amid takeover jitters, Magellan lifts on CEO and job ads hit fresh high.
Lack of staff a ‘limiting factor’: CSL
The biotech giant has deferred a marketing campaign for donors to push plasma volumes higher until new employees get trained after moves to stem existing staff attrition.
CSL diagnosis could get better from here
Australia’s biggest stock (which is not a miner or a bank) is down but by no means out.
CSL’s share price set for $400, Morgan Stanley says
A Swiss renal treatments company could elevate CSL to reclaim its spot as the biggest company on the ASX.
ASX ends flat; Ramsay soars
ASX 200 gives up gains to finish steady. Ramsay Health rallies on $20bn KKR bid. CSL, Wesfarmers and Whitehaven also strong. Rio Tinto drops after poor quarter.
ASX falls as CSL weighs; Block leads market
ASX 200 slips after early rises as US futures slide. Block ends market leader, Magellan drops amid Douglass exit, petrol prices hit fresh high and Qube lifts on $400m buyback.
CSL’s ‘super flu jab’ gets green light for use on toddlers
Australia’s health regulator has given CSL approval to inject its new generation of influenza vaccine on children as young as two years old.
Why CSL’s immune therapy trials failed
A cocktail of experimental Covid-19 drugs, administered with CSL’s own hyperimmune therapy, blurred the effectiveness of the company’s treatment in US trials.
ASX wobbles; CSL rallies as Wesfarmers sinks
ASX ends higher as Ukraine jitters spark a late selloff. CSL jumps on upgrades, Wesfarmers sinks on earnings, Telstra earnings hit and Origin brings forward Eraring closure.
CSL to take mRNA tech overseas
The nation’s biggest health group is looking offshore for mRNA development after Morrison government rejection, while its shares surged on an upbeat outlook.
Solid ASX finish; Treasury Wine, Liontown soar
ASX closed 1.1 per cent higher, driven by healthcare, real estate and financial stocks. Liontown surged on Tesla deal, CSL and Treasury Wine jumped on solid interim results and business credit demand bounced back.
Original URL: https://www.theaustralian.com.au/topics/csl/page/6